Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.

Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Cancer J. 2020 Mar/Apr;26(2):129-136
Authors: Jairam V, Park HS, Decker RH
Abstract
More than half of all patients with non-small cell lung cancer (NSCLC) have metastatic disease at the time of diagnosis. A subset of these patients has oligometastatic disease, which exists in an intermediary state between locoregional and disseminated metastatic disease. In addition, some metastatic patients on systemic therapy may have limited disease progression, or oligoprogression. Historically, treatment of metastatic NSCLC was palliative in nature, with little expectation of long-term survival. However, an accumulation of evidence over the past 3 decades now demonstrates that local ablative therapy to sites of limited metastases or progression can improve patient outcomes for this complex disease. This review examines the evidence behind local ablative therapy in oligometastatic and oligoprogressive NSCLC, with a focus on surgery, stereotactic radiotherapy, and radiofrequency ablation.
PMID: 32205537 [PubMed - in process]

Source: Cancer Journal - February 29, 2020 Category: Cancer & Oncology Authors: Jairam V, Park HS, Decker RH Tags: Cancer J Source Type: research